Overview

Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Collaborator:
Genentech, Inc.
Treatments:
Omalizumab